Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
New diarylamine KV10.1 inhibitors and their anticancer potential
ID
Gubič, Špela
(
Author
),
ID
Toplak, Žan
(
Author
),
ID
Shi, Xiaoyi
(
Author
),
ID
Dernovšek, Jaka
(
Author
),
ID
Hendrickx, Louise Antonia
(
Author
),
ID
Lopes Pinheiro-Junior, Ernesto
(
Author
),
ID
Peigneur, Steve
(
Author
),
ID
Tytgat, Jan
(
Author
),
ID
Pardo, Luis A.
(
Author
),
ID
Peterlin-Mašič, Lucija
(
Author
),
ID
Tomašič, Tihomir
(
Author
)
PDF - Presentation file,
Download
(869,51 KB)
MD5: BEBE41AD6E2A86705D89FCDD39D90418
URL - Source URL, Visit
https://www.mdpi.com/1999-4923/14/9/1963
Image galllery
Abstract
Expression of the voltage-gated potassium channel KV10.1 (Eag1) has been detected in over 70% of human cancers, making the channel a promising new target for new anticancer drug discovery. A new structural class of KV10.1 inhibitors was prepared by structural optimisation and exploration of the structure–activity relationship of the previously published hit compound ZVS-08 (1) and its optimised analogue 2. The potency and selectivity of the new inhibitors between KV10.1 and hERG were investigated using whole-cell patch-clamp experiments. We obtained two new optimised KV10.1 inhibitors, 17a and 18b, with improved nanomolar IC50 values of 568 nM and 214 nM, respectively. Compound 17a exhibited better ratio between IC50 values for hEAG1 and hERG than previously published diarylamine inhibitors. Compounds 17a and 18b moderately inhibited the growth of the KV10.1-expressing cell line MCF-7 in two independent assays. In addition, 17a and 18b also inhibited the growth of hERG-expressing Panc-1 cells with higher potency compared with MCF-7 cells. The main obstacle for newly developed diarylamine KV10.1 inhibitors remains the selectivity toward the hERG channel, which needs to be addressed with targeted drug design strategies in the future.
Language:
English
Keywords:
KV10.1
,
ion channels
,
hERG
,
SAR
,
antiproliferative activity
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
27 str.
Numbering:
Vol. 14, iss. 8, art. 1963
PID:
20.500.12556/RUL-140829
UDC:
577.352
ISSN on article:
1999-4923
DOI:
10.3390/pharmaceutics14091963
COBISS.SI-ID:
121841667
Publication date in RUL:
19.09.2022
Views:
864
Downloads:
90
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Pharmaceutics
Shortened title:
Pharmaceutics
Publisher:
MDPI
ISSN:
1999-4923
COBISS.SI-ID:
517949977
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
19.09.2022
Secondary language
Language:
Slovenian
Keywords:
KV10.1
,
ionski kanali
,
hERG
,
SAR
,
antiproliferativno delovanje
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
N1-0098-2019
Name:
Odkrivanje in mehanizem delovanja novih spojin vodnic hEag1 kalijevih kanalov s protirakavim delovanjem
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0208-2022
Name:
Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back